IM
IMM.AU Immutep Ltd
- Market cap
- AUD 33.9M
- P/E
- -
- P/B
- 0.55x
- ROE
- -128.9%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IMM.AU undervalued?
Graham numberThe Graham number of Immutep Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immutep Ltd fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-128.9%), below 10%.
ROA 0/1
Return on assets (-95.2%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-27.7%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 60.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (1.7%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.6x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Immutep Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immutep Ltd
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment …
Full company profileImmutep Ltd financial statements
Immutep Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.12M | 2.63M | 140K | 7.49M | 3.86M | 170K | 3.51M | 3.84M | 5.04M | 14.6M |
| Gross Profit | 2.42M | -7.36M | -16.5M | -15.0M | 1.79M | -1.89M | 1.44M | -37.7M | -56.4M | 12.1M |
| Operating Income | -9.35M | -11.7M | -20.4M | -16.0M | -23.5M | -38.4M | -44.9M | -88.1M | -126M | -83.9M |
| EBITDA | -8.40M | -10.5M | -18.5M | -13.9M | -17.5M | -31.9M | -42.9M | -44.3M | -62.6M | -81.4M |
| Net Income | -9.37M | -12.7M | -16.3M | -13.5M | -29.9M | -32.2M | -39.9M | -42.7M | -61.4M | -79.3M |
| EPS | -0.04 | -0.05 | -0.05 | -0.03 | -0.05 | -0.04 | -0.05 | -0.04 | -0.04 | -0.05 |
| Balance Sheet | ||||||||||
| Total Assets | 35.0M | 47.0M | 40.5M | 46.6M | 82.0M | 102M | 147M | 202M | 157M | 83.3M |
| Total Liabilities | 8.43M | 13.5M | 16.2M | 13.3M | 8.76M | 8.09M | 11.0M | 12.1M | 13.3M | 21.7M |
| Shareholders' Equity | 26.5M | 33.5M | 24.4M | 33.3M | 73.3M | 94.1M | 136M | 190M | 144M | 61.5M |
| Cash & Short-term Investments | 12.2M | 23.5M | 16.6M | 26.3M | 60.1M | 80.0M | 123M | 182M | 130M | 68.9M |
| Total Debt | 11.6M | 13.3M | 7.64M | 9.05M | 2.90M | 1.84M | 1.44M | 1.59M | 1.63M | 1.05M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -8.51M | -11.9K | -15.3M | -10.8M | -17.6M | -30.2M | -35.9M | -34.8M | -62.0M | -55.5M |
| Capital Expenditure | 6.64K | 11.9K | 41.4K | 19.3K | 15.6K | 22.9K | 47.0K | 932K | 45.8K | 92.9K |
| Free Cash Flow | -8.51M | -23.8K | -15.3M | -10.9M | -17.7M | -30.3M | -35.9M | -35.8M | -62.1M | -55.6M |
| Ratios | ||||||||||
| ROE | -35.3% | -38.0% | -66.7% | -40.4% | -40.8% | -34.2% | -29.2% | -22.5% | -42.8% | -128.9% |
| ROA | -26.8% | -27.1% | -40.1% | -28.9% | -36.5% | -31.5% | -27.1% | -21.2% | -39.1% | -95.2% |
| Net Profit Margin | -227.5% | -484.6% | -11,640.0% | -179.9% | -774.1% | -18,906.5% | -1,138.0% | -1,111.8% | -1,218.0% | -544.8% |
| Debt to Equity | 0.44x | 0.40x | 0.31x | 0.27x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immutep Ltd dividends
Immutep Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Nov 5, 2019.
Who owns Immutep Ltd
- Insiders 3.15%
- Institutions 47.61%
- Public & others 49.24%
- Shares outstanding 1.47B
- Free float 1.37B
Immutep Ltd company profile
- Company name
- Immutep Ltd
- Ticker
- IMM.AU
- ISIN
- AU000000IMM6
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Australia Square, Sydney, NSW, Australia, 2000
- Phone
- 61 2 8315 7003
- Website
- immutep.com
About Immutep Ltd
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep Ltd management
6- Mr. Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director · born 1973
- Ms. Deanne Miller LLBCOO, General Counsel & Joint Company Secretary · born 1977
- Dr. Frederic Triebel M.D., Ph.D.Chief Scientific Officer & Executive Director · born 1955
- Mr. Christian Mueller BBA, MSc.Chief Development Officer
- Dr. Stephan Winckels M.D., Ph.D.Chief Medical Officer
- Ms. Indira NaiduJoint Company Secretary